Navigation Links
Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge
Date:4/1/2015

PARSIPPANY, N.J., April 1, 2015 /PRNewswire/ -- Daiichi Sankyo, Inc., the US subsidiary of Daiichi Sankyo Company, Ltd, announced today that it will merge with its US-based sister company, Asubio Pharmaceuticals, Inc.  As a result, Asubio Pharmaceuticals, Inc. projects will be integrated into the Daiichi Sankyo global development organization, led by Mahmoud Ghazzi, MD, PhD.

Asubio Pharmaceuticals' parent company, Asubio Pharma Co., Ltd, which is based in Japan, will continue to operate as a wholly owned subsidiary of Daiichi Sankyo Co., Ltd., with a focus on discovery research.

Asubio Pharmaceuticals, Inc.'s ongoing clinical trial in patients with acute spinal cord injury, ASBI 603ASCENT Study (SUN13837) has completed enrollment.  An analysis and dissemination of the data will be managed by Daiichi Sankyo. 

"In line with the Daiichi Sankyo five-year business plan to optimize our business of delivering innovative treatments to patients, consolidating the current Asubio US projects under the company's overall R&D organization helps us streamline our operations," said Glenn Gormley, MD, PhD, Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Company, Ltd., and Executive Chairman and President, Daiichi Sankyo, Inc.

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, dyslipidemia and bacterial infections used by patients around the world, the Group has also launched treatments for thrombotic disorders and is building new product franchises. Furthermore, Daiichi Sankyo research and development is focused on bringing forth novel therapies in oncology and cardiovascular-metabolic diseases, including biologics. The Daiichi Sankyo Group has created a "Hybrid Business Model," to respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.


'/>"/>
SOURCE Daiichi Sankyo, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
3. Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
4. Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
5. Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
6. Charleston Laboratories and Daiichi Sankyo Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
7. Daiichi Sankyo to Acquire Ambit Biosciences
8. Daiichi Sankyo adquiere Ambit Biosciences
9. Daiichi Sankyo wird Ambit Biosciences übernehmen
10. Daiichi Sankyo va acquérir Ambit Biosciences
11. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Completion of a Pharmacokinetics Study on CL-108
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2020)... ... September 03, 2020 , ... Q&J Face Masks ... ), an aerosol and engineering lab, conducted tests on Q&J’s personal face mask ... virus than many other masks. Q&J face masks have both mechanical filtering and ...
(Date:9/2/2020)... , ... September 02, 2020 , ... U.S. Dermatology ... Lee . Dr. Lee will work at Bethesda Dermatopathology Lab. , ... B.A. from the University of California, Berkley. He went on to receive his M.D. ...
(Date:9/1/2020)... ... September 01, 2020 , ... Breast and ovarian cancers are ... (CDC), About 3% of breast cancers (about 7,500 women per year) and 10% of ... and BRCA2 genes. Both genes are detectable in the Women’s Excellence Genetic Testing ...
Breaking Medicine Technology:
(Date:8/31/2020)... ... ... Just found out your dear friend has cancer? , It’s hard to hear your doctor ... their diagnosis. Once the shock wears off, the questions and fears can be overwhelming. , ... ways to help? Words are failing me. I’m scared. I want to DO something. , ...
(Date:8/31/2020)... ... August 31, 2020 , ... Smile ... dental groups in the United States, today announced the grand opening of another ... , Patients will enjoy convenient hours, a comfortable office, and full-service care ...
(Date:8/31/2020)... ... 31, 2020 , ... Bonde Innovations, LLC, a venture-backed developer ... failure, today announced that the company has been awarded a Phase 1 Small ... Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). The ...
(Date:8/28/2020)... ... 28, 2020 , ... With in-person gluten-free events being canceled ... the specialty-diet community connect with great, gluten-free brands. At the Online Nourished ... with brands & watch over 50 educational classes... all online from the comfort ...
(Date:8/27/2020)... LAS VEGAS (PRWEB) , ... August 27, 2020 ... ... open their doors! Sikara Medspa is a leading aesthetic and wellness retreat. The ... Summerlin area and surrounding areas of Las Vegas. , Designed to be ...
Breaking Medicine News(10 mins):